$NKTR News

Canaccord Genuity Initiates Coverage On Nektar Therapeutics with Buy Rating, Announces Price Target of $153

Nektar Therapeutics Announces Start of Phase 3 ZENITH AD Program Evaluating Novel Regulatory T-Cell Biologic Rezpegaldesleukin in Moderate-to-Severe Atopic Dermatitis

Nektar Therapeutics Initiates First Two Global Registrational Trials, ZENITH AD-1 and ZENITH AD-2, In Its Phase 3 Program For Rezpegaldesleukin; Initial Phase 3 Topline Data Expected In Mid-2028 With BLA Submission Targeted For 2029

NKTR Stock Clocks Best Day In Over 2 Months As Investors Await Upcoming Clinical Data In Eczema

Nektar Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

What a $1.2 Million Insider Sale Means for Nektar With Shares Up 160% This Past Year

A Look At Nektar Therapeutics (NKTR) Valuation After Recent Share Price Volatility

What Makes Nektar Therapeutics (NKTR) a Promising Mid-Cap Healthcare Stock

Nektar Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference in New York

Why I'm Still Neutral On Nektar Therapeutics After Alopecia Areata Extension Data

Assessing Nektar Therapeutics (NKTR) Valuation After Strong REZPEG Prospects And Recent Share Price Momentum

Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $80

Nektar Therapeutics To Offer Up To $150M In Common Stock Via Equity Distribution Agreement

Nektar Therapeutics Q1 2026 Earnings Call Summary

Piper Sandler Maintains Overweight on Nektar Therapeutics, Raises Price Target to $192

Nektar Therapeutics Q1 Earnings Call Highlights

Nektar Therapeutics (NKTR) Q1 2026 Earnings Call Transcript

NEKTAR THERAPEUTICS (NASDAQ:NKTR) Q1 Earnings Beat Revenue Estimates but EPS Miss Drags Stock Lower

Nektar (NKTR) Q1 2026 Earnings Transcript

Nektar Therapeutics Reports First Quarter 2026 Financial Results